ASCO GU 2025

Combining ARPi with PARPi - discussing final OS of…

What's the role of Enzalutamide in radioligand therapy?

Radical Prostatectomy VS RT in HRPC

Who benefits most from ARPIs?

Darolutamide + ADT and Doetaxel improves survivas in…

Improved Survival with Enzalutamide + Lutetium

MDT in OMPC

Final OS analyses

ENZA-p showed OS benefit and improvement in QoL…

Hypo-gonadism bad for survival?

Durvalumab in UTUC

Fish-oil supplement for pts on active surveillance

Darolutamide + ADT reduces risk of progression or death…

Radiation vs surgery in high risk prostate cancer

Testosterone Recovery

OS in the TALAPRO-2 trial

ARPI for which patients?

Mevrometostat + Enza: New option for mCRPC

Testosterone Recovery after ADT and OS

Local radiotherapy of oligoprogressive mCRPC

Mevrometostat - a new EZH2 inhibitor in mCRPC

Final OS data for TALA + Enza

UTUC de Neoadj. Durvalumab+Kemo

Yuksek risk PCa da RP vs RT

Enza+Lu ile artmis sagkalim

Hangi hastalarda ADT+ARPI

Oligometastatik PCa da MDT

KIM-1 - The most interesting biomarker for RCC?

Triplet combination in RCC - there's no free lunch with…

New data but no new conclusion

Advanced Renal Cell Cancer: Adding more drugs does not…

New agents / new mode of actions

New data nccRCC

KIM-1 in CheckMate 214

Firstline Update Kidney Cancer

Proactive coaching of patients with TKI +/- IO therapy

Casdatifan in refracting RCC

KIM-1 in mRCC

AVION trial at mRCC

Biomarcadores prognósticos y predictivos en el CCRm: en…

New data, but no new insights for adjuvant treatment of…

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

Exploratory analyses of pCR in NIAGARA: who benefits…

ADC + ICI - The future for MIBC?

Adjuvant Nivo - independent from previous therapy

ASCO GU 25 - Summary: Urothelial Cancer

A possible new standard for mUC

New drugs in mUC: The active field of ADCs

HER2 - new marker for bladder preservation

Neoadjuvant treatment for UTUC

Promising combination for perioperative setting

Sacituzumab Tirumotecan shows promising antitumor…

New FGFR3 inhibitor

The role of ctDNA in bladder cancer

Phase 2 Mevrometastat

Preliminary results of neoadjuvant chemoimmunotherapy…

EV-Pembro continues to be the standard for mTCC

Bladder-sparing approaches - are we there yet?

Nivo adjuvant in MIBC - a new standard

Updates neo/adjuvant therapy in MIBC

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Nuevos fármacos en mUC: El campo activo de las ADCs

Testicular cancer: Reinventing the wheel

Cáncer de testículo: reinventar la rueda